1-20 of 84
Sort by
News

Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
September 2023
View News titled, Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL
News

Venetoclax, Obinutuzumab Improve HRQoL in CLL Despite Existing Geriatric Impairments

Leah Lawrence
Published: 2023
Abstract
September 2023
View News titled, Venetoclax, Obinutuzumab Improve HRQoL in CLL Despite Existing Geriatric Impairments
News

Rusfertide Effectively Supports Hematocrit Control in PV

Brandon May
Published: 2023
Abstract
Mid-July 2023
View News titled, Rusfertide Effectively Supports Hematocrit Control in PV
News

Are Hypomethylating Agents the Best First-Line Choice for Treating CMML?

Leah Lawrence
Published: 2023
Abstract
July 2023
View News titled, Are Hypomethylating Agents the Best First-Line Choice for Treating CMML?
News

Studies Provide Insights Into BTK Inhibitor Resistance

Leah Lawrence
Published: 2023
Abstract
April 2023
View News titled, Studies Provide Insights Into BTK Inhibitor Resistance
News

Early MMR With TKI Therapy Not Necessary to Normalize Survival in Patients Over 60 With CML

Khylia Marshall
Published: 2023
Abstract
April 2023
View News titled, Early MMR With TKI Therapy Not Necessary to Normalize Survival in Patients Over 60 With CML
News

Decitabine Yields Similar Survival Despite Superior Responses Versus HU in MP-CMML

Thomas R. Collins
Published: 2023
Abstract
March 2023
View News titled, Decitabine Yields Similar Survival Despite Superior Responses Versus HU in MP-CMML
News

Vemurafenib Retreatment Deemed Effective in R/R Hairy Cell Leukemia

Brandon May
Published: 2022
Abstract
November 2022
View News titled, Vemurafenib Retreatment Deemed Effective in R/R Hairy Cell Leukemia
News

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Shows Promise for Untreated, High-Risk CLL

Published: 2022
Abstract
February 2022
View News titled, Ibrutinib, Venetoclax, and Obinutuzumab Triplet Shows Promise for Untreated, High-Risk CLL
News

Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Published: 2021
View News titled, Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
News

How I Treat In Brief: Atypical Chronic Myeloid Leukemia

Published: 2021
View News titled, How I Treat In Brief: Atypical Chronic Myeloid Leukemia
News

No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

Published: 2021
View News titled, No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia
News

FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML

Published: 2021
View News titled, FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML
News

FDA Expands Approval for Bosutinib to Include Early-Phase CML

Published: 2021
View News titled, FDA Expands Approval for Bosutinib to Include Early-Phase CML
News

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

Published: 2021
View News titled, Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies
News

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Published: 2021
View News titled, Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML
News

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

Published: 2021
View News titled, Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML
News

FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML

Published: 2021
View News titled, FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML
News

What are the treatment options for a pregnant woman with chronic-phase CML?

Published: 2021
View News titled, What are the treatment options for a pregnant woman with chronic-phase CML?
News

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Published: 2021
View News titled, Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment